Phase I Study of Oral Clofarabine for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Trial Profile

Phase I Study of Oral Clofarabine for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Apr 2009 Actual initiation date changed from 1 Nov 2008 to 22 Oct 2008 as reported by M.D. Anderson Cancer Center.
    • 01 Dec 2008 New source identified and integrated (ClinicalTrials.gov record NCT00800566).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top